modelDexamethasone_1
Extends from Pharmacolibrary.Drugs.ATC.H.H02AB02_1.
Information
| name: | Dexamethasone_1 | |
| ATC code: | H02AB02_1 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 8 | mg |
| volume of distribution: | 98.7 | L |
| clearance: | 8.0 | L/h |
| other parameters in model implementation | ||
Dexamethasone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressant properties. It is used in the treatment of a variety of conditions, including autoimmune disorders, allergies, certain cancers, cerebral edema, and is commonly employed in the management of severe COVID-19 and as adjunctive therapy in chemotherapy-induced nausea. Dexamethasone is an approved drug and remains in clinical use.
Pharmacokinetics
Pharmacokinetic parameters for intravenous administration of dexamethasone in healthy adult volunteers.
References
Li, L, et al., & Endeman, H (2023). Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: Does inflammation play a role?. Journal of critical care 78 154395–None. DOI:10.1016/j.jcrc.2023.154395 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37542750
Guthrie, S (1991). The impact of dexamethasone pharmacokinetics on the DST: a review. Psychopharmacology bulletin 27(4) 565–576. PUBMED:https://pubmed.ncbi.nlm.nih.gov/1813902
Nijstad, AL, et al., & Zwaan, CM (2022). Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 30(12) 9991–9999. DOI:10.1007/s00520-022-07423-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36287279
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)